Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Código da empresaDNA
Nome da EmpresaGinkgo Bioworks Holdings Inc
Data de listagemApr 19, 2021
CEODr. Jason Kelly
Número de funcionários834
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 19
Endereço27 Drydock Avenue
CidadeBOSTON
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal02210
Telefone18774425362
Sitehttps://investors.ginkgobioworks.com/
Código da empresaDNA
Data de listagemApr 19, 2021
CEODr. Jason Kelly
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados